Conference Call with Anupam Rasayan India Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Anupam Rasayan India announced Q3FY25 results Total revenue for Q3FY25 was at Rs 3,866 million as compared to Rs 2,979 million in Q3FY24; up 30% YoY. EBITDA (incl. other income) was at Rs 1,208 million in Q3FY25 as compared to Rs 815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter. Profit After Tax was at Rs 542 million in Q3FY25 as compared to Rs 260 million in Q3FY24; up 108% YoY. Anand Desai, Managing Director, Anupam Rasayan commented, “Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market." "With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26. Result PDF